Advanced Medical Isotopes Corporation Signs 1-Year Option to License Injectable Radiogel for High-dose Interstitial Radiation Therapy Developed at Pacific Northwest National Laboratory
2/28/2011 9:49:19 AM
KENNEWICK, Wash., Feb. 28, 2011 (GLOBE NEWSWIRE) -- James Katzaroff, Chairman and Chief Executive Officer of Advanced Medical Isotope Corporation (OTCBB:ADMD), a company engaged in the production and distribution of medical isotopes, has signed an option agreement with Battelle Memorial Institute, operator of Pacific Northwest National Laboratory (PNNL) for rights to an injectable "Radiogel" for High-dose Interstitial Radiation Therapy. Upon exercise of the option and execution of an exclusive license with Battelle, AMIC will have the exclusive right to further develop the technology, which is a microsphere-embedded, injectable polymer solution designed to maximize the radiation dose to cancerous tumors that cannot be removed surgically.
comments powered by